[go: up one dir, main page]

IN2012DN01449A - - Google Patents

Download PDF

Info

Publication number
IN2012DN01449A
IN2012DN01449A IN1449DEN2012A IN2012DN01449A IN 2012DN01449 A IN2012DN01449 A IN 2012DN01449A IN 1449DEN2012 A IN1449DEN2012 A IN 1449DEN2012A IN 2012DN01449 A IN2012DN01449 A IN 2012DN01449A
Authority
IN
India
Prior art keywords
diagnostic
blood vessels
conditions associated
pathological conditions
cancerous tissue
Prior art date
Application number
Inventor
Luisa Petersen Anncatrine
Hedengran Rasmussen Palle
Rosager Henriksen Jonas
Kjær Andreas
Lars Andresen Thomas
Original Assignee
Univ Denmark Tech Dtu
Rigshospitalet
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Denmark Tech Dtu, Rigshospitalet filed Critical Univ Denmark Tech Dtu
Publication of IN2012DN01449A publication Critical patent/IN2012DN01449A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1241—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
    • A61K51/1244—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins microparticles or nanoparticles, e.g. polymeric nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/025—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus inorganic Tc complexes or compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1217—Dispersions, suspensions, colloids, emulsions, e.g. perfluorinated emulsion, sols
    • A61K51/1234—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Dispersion Chemistry (AREA)
  • Nanotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Manufacturing Of Micro-Capsules (AREA)

Abstract

The present invention relates to a novel composition and method for loading delivery systems such as liposome compositions with radionuclides useful in targeted diagnostic and/or therapy of target site  such as cancerous tissue and  in general  pathological conditions associated with leaky blood vessels. The composition and methods of the invention find particular use in diagnosing and imaging cancerous tissue and  in general  pathological conditions associated with leaky blood vessels in a subject. The present invention provides a new diagnostic tool for the utilization of positron emission tomography (PET) imaging technique. One specific aspect of the invention is directed to a method of producing nanoparticles with desired targeting properties for diagnostic and/or radio-therapeutic applications.
IN1449DEN2012 2009-07-17 2010-07-16 IN2012DN01449A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA200900879 2009-07-17
US30078210P 2010-02-02 2010-02-02
EP10152394 2010-02-02
PCT/DK2010/050192 WO2011006510A1 (en) 2009-07-17 2010-07-16 Loading technique for preparing radionuclide and ionophore containing liposomes in which the ionophore is 2-hydroxyquionoline (carbostyril) or structurally related 2-hydroxyquinolines

Publications (1)

Publication Number Publication Date
IN2012DN01449A true IN2012DN01449A (en) 2015-06-05

Family

ID=43448962

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1449DEN2012 IN2012DN01449A (en) 2009-07-17 2010-07-16

Country Status (7)

Country Link
US (2) US8920775B2 (en)
EP (1) EP2453927B1 (en)
JP (1) JP5872466B2 (en)
AU (1) AU2010272957B2 (en)
CA (1) CA2768444A1 (en)
IN (1) IN2012DN01449A (en)
WO (1) WO2011006510A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9226984B2 (en) 2010-12-14 2016-01-05 Technical University of Denmark and Rigshospitalet Entrapment of radionuclides in nanoparticle compositions
AU2013249307B2 (en) 2012-04-17 2017-11-09 Merrimack Pharmaceuticals, Inc. Compositions and methods for non-invasive imaging
EP2922578B1 (en) * 2012-11-21 2018-12-12 Serene, Llc Tin-117m comprising somatostatin receptor binding compounds
WO2014164712A1 (en) 2013-03-11 2014-10-09 Wayne State University Formation and uses of europium
WO2017027064A1 (en) * 2015-08-12 2017-02-16 The General Hospital Corporation 8-hydroxyquinoline derivatives as diagnostic and therapeutic agents
CA3015663A1 (en) * 2016-03-07 2017-09-14 Memorial Sloan Kettering Cancer Center Bone marrow-, reticuloendothelial system-, and/or lymph node-targeted radiolabeled liposomes and methods of their diagnostic and therapeutic use
US20220023450A1 (en) * 2018-09-11 2022-01-27 Memorial Sloan Kettering Cancer Center Bone marrow-, reticuloendothelial system-, and/or lymph node-targeted radiolabeled liposomes and methods of their diagnostic and therapeutic use
US11478493B2 (en) * 2019-03-08 2022-10-25 University Of South Carolina Fabrication and application of a hetero-targeted nano-cocktail with traceless linkers
EP4536278A2 (en) 2022-06-07 2025-04-16 Actinium Pharmaceuticals, Inc. Bifunctional chelators and conjugates

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1314209C (en) 1987-11-04 1993-03-09 Gary Fujii Composition and method for use for liposome encapsulated compounds for neutron capture tumor therapy
US5688488A (en) 1989-04-03 1997-11-18 Purdue Research Foundation Composition and method for tumor imaging
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5525232A (en) 1990-03-02 1996-06-11 The Liposome Company, Inc. Method for entrapment of cationic species in lemellar vesicles
JPH075561B2 (en) * 1991-12-17 1995-01-25 工業技術院長 Diamide derivative of α-amino acid
US5837282A (en) * 1996-10-30 1998-11-17 University Of British Columbia Ionophore-mediated liposome loading
US6306393B1 (en) * 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US5945502A (en) 1997-11-13 1999-08-31 Xerox Corporation Electroluminescent polymer compositions and processes thereof
NO312708B1 (en) 2000-02-21 2002-06-24 Anticancer Therapeutic Inv Sa Radioactive liposomes for therapy
DE10012782A1 (en) * 2000-03-16 2001-09-20 Boellhoff Gmbh Connection method for joining a thermoplastic plastic connector onto a thermoplastic component involves welding together matching faces of a connector projection and a component shoulder
WO2004082627A2 (en) 2003-03-18 2004-09-30 Ethicon, Inc. ENZYME REPLACEMENT THERAPY WITH 17-β-HYDROXYSTEROID DEHYDROGENASE-TYPE 2
EP1603535A4 (en) * 2003-03-18 2008-10-15 Ethicon Inc Aromatase inhibitor diagnosis and therapy
US20060040980A1 (en) 2004-08-20 2006-02-23 Lind Stuart E Ionophores as cancer chemotherapeutic agents
EP1796729A4 (en) * 2004-10-06 2010-12-08 Bc Cancer Agency LIPOSOME WITH IMPROVED ARZNE RETENTION FOR THE TREATMENT OF CANCER
GB0423565D0 (en) * 2004-10-22 2004-11-24 Algeta As Formulation
ITMI20050328A1 (en) 2005-03-03 2006-09-04 Univ Degli Studi Milano PEPTIDOMIMETRIC COMPOUNDS AND PREPARATION OF BIOLOGICALLY ACTIVE DERIVATIVES
JP2009534309A (en) * 2006-03-31 2009-09-24 マサチューセッツ インスティテュート オブ テクノロジー System for targeted delivery of therapeutic agents
TW200922630A (en) * 2007-09-26 2009-06-01 Nat Health Research Institutes Liposome compositions useful for tumor imaging and treatment
WO2009140215A2 (en) * 2008-05-11 2009-11-19 Geraghty, Erin Method for treating drug-resistant bacterial and other infections with clioquinol, phanquinone, and related compounds
MX360391B (en) * 2011-10-31 2018-10-31 Mallinckrodt Llc Combinational liposome compositions for cancer therapy.

Also Published As

Publication number Publication date
JP2012533523A (en) 2012-12-27
CA2768444A1 (en) 2011-01-20
EP2453927A1 (en) 2012-05-23
US20120213698A1 (en) 2012-08-23
AU2010272957B2 (en) 2016-03-03
EP2453927A4 (en) 2013-01-23
US20150202336A1 (en) 2015-07-23
EP2453927B1 (en) 2019-05-15
JP5872466B2 (en) 2016-03-01
WO2011006510A1 (en) 2011-01-20
US8920775B2 (en) 2014-12-30
AU2010272957A1 (en) 2012-03-08

Similar Documents

Publication Publication Date Title
IN2012DN01449A (en)
Thompson et al. Practice-changing radiation therapy trials for the treatment of cancer: where are we 150 years after the birth of Marie Curie?
Castaldi et al. Can “early” and “late” 18F-FDG PET–CT be used as prognostic factors for the clinical outcome of patients with locally advanced head and neck cancer treated with radio-chemotherapy?
WO2008008483A3 (en) Dendrimer based compositions and methods of using the same
NZ605674A (en) X-ray imaging at low contrast agent concentrations and/or low dose radiation
EP3208615A3 (en) Uses of labeled hsp90 inhibitors
PH12012502044A1 (en) Robo1-fc fusion protein and use thereof for treating tumours
PH12015500252A1 (en) Niclosamide for the treatment of solid tumors
NZ710436A (en) Biospecific agents for bone
WO2012109466A3 (en) Long non-coding rna spry4-it1 as a diagnostic and therapeutic agent
Li et al. Pre-treatment metabolic tumor volume and total lesion glycolysis are useful prognostic factors for esophageal squamous cell cancer patients
WO2015158652A8 (en) S100p and hyluronic acid as biomarkers for metastatic breast cancer
CO6382138A2 (en) N-CADHERINA: WHITE FOR DIAGNOSIS AND CANCER THERAPY
PH12013501017A1 (en) Compounds for use in imaging, diagnosing and/or treatment of diseases of the central nervous system
Demirci et al. The nodal standard uptake value (SUV) as a prognostic factor in head and neck squamous cell cancer
WO2010141143A3 (en) Engineered avirulent bacteria strains and use in medical treatments
De Waele et al. Response assessment of hormonal therapy in prostate cancer by [11C] choline PET/CT
WO2007136856A3 (en) Heyl as a therapeutic target and a diagnostic marker for neoplasia and uses therefor
UA56157U (en) method for rendering aid to patients with post-traumatic otoliquorea acute period of craniocerebral traumas at fractures of temporal bone
UA60606U (en) method for stereotactic biopsy of brain focal formations of deep localization
MX336321B (en) 99-mtc-tat-bombesin as a novel radiopharmaceutical for the early detection of breast cancer.
Emmett et al. Imaging for melanoma and non-melanoma skin cancers
Majoros et al. Progress in cancer nanotechnology
Iwahashi et al. A Case of MALT Lymphoma Occurrence in the False Vocal Cord
Gelezhe et al. CURRENT CRITERIA OF RADIAL DIAGNOSTICS TO ASSESS THE EFFECTIVENESS OF SPECIFIC CANCER TREATMENT